Close Menu

NEW YORK (GenomeWeb News) – Qiagen announced after the close of the market on Friday that the US Food and Drug Administration has cleared for marketing its therascreen KRAS RGQ PCR Kit to be sold as a companion diagnostic test for Erbitux (cetuximab), a drug used for treating colorectal cancer.

Erbitux is an EGFR inhibitor marketed in the US by Bristol-Myers Squibb along with Eli Lily and its Imclone Systems unit. Outside of the US and Canada, it is sold by Germany's Merck KGaA.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.

Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.

Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.

In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.